In this study we have investigated for the first time the influence that ER tissue expression may have on the baseline host immune cytokines and nuclear magnetic resonance (1H NMR) metabolomic profiles [33,34] in a highly homogeneous population of HER2-positive BC patients enrolled for NATC treatment. Here, ERBB2 is linked to breast cancer.